$SLRX
Salarius Pharmaceuticals, Inc.

2020 Q4 Form 10-Q Financial Statement

#000161521920000113 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $1.480M $1.378M $874.9K
YoY Change 42.31% 57.52% 86.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.210M $1.330M $3.490M
YoY Change -31.25% -61.89% 85.64%
% of Gross Profit
Research & Development $2.020M $1.804M $1.141M
YoY Change 50.75% 58.09% 222.65%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $3.240M $3.137M $4.635M
YoY Change 4.52% -32.33% 492.3%
Operating Profit -$1.759M -$3.760M
YoY Change -53.23% 1099.36%
Interest Expense -$10.00K -$3.230K -$752.00
YoY Change -105.56% 329.52% -112.4%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change
Pretax Income -$1.770M -$1.720M -$2.630M
YoY Change -5.85% -34.6% -0.38%
Income Tax
% Of Pretax Income
Net Earnings -$1.770M -$1.717M -$2.628M
YoY Change -5.85% -34.67% 754.68%
Net Earnings / Revenue -119.59% -124.55% -300.33%
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$113.6K -$0.10 -$728.5K
COMMON SHARES
Basic Shares Outstanding 19.84M shares 17.97M shares 18.07M shares
Diluted Shares Outstanding 17.97M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.10M $9.600M $4.000M
YoY Change 200.0% 140.0% -69.23%
Cash & Equivalents $11.12M $9.558M $4.000M
Short-Term Investments
Other Short-Term Assets $137.8K $139.9K $119.0K
YoY Change 1.27% 17.6% -76.21%
Inventory
Prepaid Expenses
Receivables $3.900M $3.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $15.80M $13.92M $5.239M
YoY Change 236.47% 165.66% -61.71%
LONG-TERM ASSETS
Property, Plant & Equipment $22.64K $15.64K $28.14K
YoY Change -9.5% -44.45% -77.86%
Goodwill $8.866M $8.866M $8.866M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $247.1K $262.5K $324.5K
YoY Change -19.94% -19.11% 224.51%
Total Long-Term Assets $9.136M $9.144M $9.219M
YoY Change -0.7% -0.81% 3533.86%
TOTAL ASSETS
Total Short-Term Assets $15.80M $13.92M $5.239M
Total Long-Term Assets $9.136M $9.144M $9.219M
Total Assets $24.93M $23.06M $14.46M
YoY Change 79.44% 59.52% 3.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.854M $1.195M $1.643M
YoY Change 3.51% -27.27% 28.44%
Accrued Expenses $400.0K $400.0K $200.0K
YoY Change 100.0% 100.0% -87.5%
Deferred Revenue $0.00 $0.00 $1.580M
YoY Change -100.0% -100.0%
Short-Term Debt $500.0K $800.0K $700.0K
YoY Change 0.0% 14.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.800M $2.500M $4.700M
YoY Change -15.15% -46.81% 62.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.800M $2.500M $4.700M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.773M $2.457M $4.721M
YoY Change -16.31% -47.95% 63.47%
SHAREHOLDERS EQUITY
Retained Earnings -$19.43M -$17.66M -$10.19M
YoY Change 60.88% 73.26% -92.22%
Common Stock $2.381K $1.981K $3.756K
YoY Change 427.94% -47.26% 107.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.16M $20.61M $9.737M
YoY Change
Total Liabilities & Shareholders Equity $24.93M $23.06M $14.46M
YoY Change 79.44% 59.52% 3.73%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$1.770M -$1.717M -$2.628M
YoY Change -5.85% -34.67% 754.68%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$1.370M -$2.760M -$5.540M
YoY Change -48.11% -50.18% 98.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $5.610M
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $5.610M
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.930M 5.090M -210.0K
YoY Change 23.11% -2523.81%
NET CHANGE
Cash From Operating Activities -1.370M -2.760M -5.540M
Cash From Investing Activities 0.000 0.000 5.610M
Cash From Financing Activities 2.930M 5.090M -210.0K
Net Change In Cash 1.560M 2.330M -140.0K
YoY Change -700.0% -1764.29% -94.98%
FREE CASH FLOW
Cash From Operating Activities -$1.370M -$2.760M -$5.540M
Capital Expenditures $0.00
Free Cash Flow -$1.370M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001615219
dei Local Phone Number
LocalPhoneNumber
834-6992
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36812
dei Entity Registrant Name
EntityRegistrantName
SALARIUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5087339
dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite X
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
dei City Area Code
CityAreaCode
832
dei Security12b Title
Security12bTitle
Common Stock, $ 0.0001 par value
dei Trading Symbol
TradingSymbol
SLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19843866 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9557813 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3738900 USD
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
3212678 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1148667 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955899 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
13919158 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
4694799 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15635 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25016 USD
CY2020Q3 us-gaap Goodwill
Goodwill
8865909 USD
CY2019Q4 us-gaap Goodwill
Goodwill
8865909 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
262509 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308674 USD
CY2020Q3 us-gaap Assets
Assets
23063211 USD
CY2019Q4 us-gaap Assets
Assets
13894398 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1195063 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1790966 USD
CY2020Q3 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
448862 USD
CY2019Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
160783 USD
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
761096 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
502332 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
541701 USD
CY2020Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
52224 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
317762 USD
CY2020Q3 us-gaap Liabilities
Liabilities
2457245 USD
CY2019Q4 us-gaap Liabilities
Liabilities
3313544 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19821716 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4519533 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19818912 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4511174 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1981 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
451 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
38265391 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22657103 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17661406 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12076700 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
20605966 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10580854 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23063211 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13894398 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1378239 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
874949 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3754379 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3754379 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2426362 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1803682 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1140909 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4890375 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4890375 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2680982 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2680982 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1333062 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3494205 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4893021 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4893021 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5950431 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5950431 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3136744 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4635114 USD
us-gaap Operating Expenses
OperatingExpenses
9783396 USD
us-gaap Operating Expenses
OperatingExpenses
8631413 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1758505 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3760165 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6029017 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6205051 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-45103 USD
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265538 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265538 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
CY2019Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
179027 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3230 USD
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-752 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-254 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-254 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18413 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18413 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1716632 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2630069 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5584706 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5055790 USD
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2348 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2348 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1716632 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2627721 USD
us-gaap Net Income Loss
NetIncomeLoss
-5584706 USD
us-gaap Net Income Loss
NetIncomeLoss
-5053442 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17968664 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3605913 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13833410 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13833410 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3002736 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3002736 shares
us-gaap Net Income Loss
NetIncomeLoss
-5584706 USD
us-gaap Net Income Loss
NetIncomeLoss
-5053442 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12699 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123174 USD
us-gaap Share Based Compensation
ShareBasedCompensation
149660 USD
us-gaap Share Based Compensation
ShareBasedCompensation
579721 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265538 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-690 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1169 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3212678 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-799210 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
206956 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-607904 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-593351 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
288079 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-235817 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1517 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-541701 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2426361 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8937879 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8943538 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
5403634 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
204274 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5607908 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
14810945 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1508179 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
0 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
133594 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
636214 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
690367 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
171060 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14756792 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1203525 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5818913 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2132105 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3738900 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6131781 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9557813 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3999676 USD
us-gaap Interest Paid Net
InterestPaidNet
6615 USD
us-gaap Interest Paid Net
InterestPaidNet
6867 USD
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
12001 USD
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
0 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
110474 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2869412 USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
949131 USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
920217 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1271114 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4377591 USD
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110474 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
35407 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1522076 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1730282 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
99758 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6034 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-903645 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
732913 USD
CY2019Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
11093561 USD
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
538280 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2627721 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
9737033 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10580854 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9467166 USD
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
38409 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2083816 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
18002613 USD
CY2020Q2 flks Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
578714 USD
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
32905 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1784258 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
16854974 USD
CY2020Q3 flks Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
57500 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5331778 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
78346 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1716632 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
20605966 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1000000.0 USD
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
110474 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2019Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div>
CY2019Q3 flks Class Of Warrant Or Right Period Warrants Or Rights Unexercisable
ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable
P6M
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3754379 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2426362 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-5584706 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10075278 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
389488 shares
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7802709 USD
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.40
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-2.08
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
3212678 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0 USD
CY2020Q3 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
36518 USD
CY2019Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
202743 USD
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
972236 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
617096 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
139913 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
136060 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1148667 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955899 USD
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
761096 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
502332 USD
CY2016Q2 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
18700000 USD
CY2016Q2 flks Revenue From Grants Award Term
RevenueFromGrantsAwardTerm
P3Y
CY2020Q3 flks Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
0.01
CY2020Q3 flks Revenue From Grants Matching Funds Requirement
RevenueFromGrantsMatchingFundsRequirement
0.50
CY2020Q3 flks Revenue From Grants Aggregate Amount Received
RevenueFromGrantsAggregateAmountReceived
9600000 USD
CY2020Q3 flks Revenue From Grants Aggregate Amount Received Current Funding Available
RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable
9100000 USD
flks Revenue From Grants Current Funding Received
RevenueFromGrantsCurrentFundingReceived
0 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
541701 USD
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
3212678 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0 USD
CY2019Q3 flks Class Of Warrant Or Right Threshold Consecutive Trading Days
ClassOfWarrantOrRightThresholdConsecutiveTradingDays
10 trading_Days
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6200000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4377591 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10617 USD
CY2019Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
142711 shares
CY2020Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.17
CY2020Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y3M21D
CY2019Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y21D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
182000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
541118 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000 shares
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
92007 USD
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
623561 USD
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
15679 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0048
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0037
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0038
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1317
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2420
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2542
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
166233 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.42
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M10D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
743118 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36613 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30766 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
841972 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M25D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
69813 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M4D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
358869 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D

Files In Submission

Name View Source Status
0001615219-20-000113-index-headers.html Edgar Link pending
0001615219-20-000113-index.html Edgar Link pending
0001615219-20-000113.txt Edgar Link pending
0001615219-20-000113-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20200930.htm Edgar Link pending
flks-20200930.xsd Edgar Link pending
flks-20200930_cal.xml Edgar Link unprocessable
flks-20200930_def.xml Edgar Link unprocessable
flks-20200930_htm.xml Edgar Link completed
flks-20200930_lab.xml Edgar Link unprocessable
flks-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx20200930ex-311.htm Edgar Link pending
slrx20200930ex-312.htm Edgar Link pending
slrx20200930ex-321.htm Edgar Link pending